Evaluation of the mutagenicity of medroxyprogesterone acetate in vitro and in vivo.
Medroxyprogesterone acetate (CAS 71-58-9) is used for cyclic hormone substitution during the menopause and in hormone therapy of breast cancer. The test substance was investigated for its mutagenic potential in a series of test systems according to the current EC guidelines. There were no indications for a mutagenic potential of medroxyprogesterone acetate.
Herzog
R
R
Henning Berlin GmbH, Germany.
Leuschner
J
J
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000648:ultrastructure; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D066298:In Vitro Techniques; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000633:toxicity*; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D017354:Point Mutation / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012486:Salmonella typhimurium / Q000187:drug effects / Q000235:genetics
D009153:Mutagens; D017258:Medroxyprogesterone Acetate; D007041:Hypoxanthine Phosphoribosyltransferase